Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

被引:691
|
作者
Huang, Jinghe [1 ]
Ofek, Gilad [2 ]
Laub, Leo [1 ]
Louder, Mark K. [2 ]
Doria-Rose, Nicole A. [2 ]
Longo, Nancy S. [2 ]
Imamichi, Hiromi [1 ]
Bailer, Robert T. [2 ]
Chakrabarti, Bimal [3 ]
Sharma, Shailendra K. [3 ]
Alam, S. Munir [4 ]
Wang, Tao [2 ]
Yang, Yongping [2 ]
Zhang, Baoshan [2 ]
Migueles, Stephen A. [1 ]
Wyatt, Richard [3 ]
Haynes, Barton F. [4 ]
Kwong, Peter D. [2 ]
Mascola, John R. [2 ]
Connors, Mark [1 ]
机构
[1] NIAID, HIV Specif Immun Sect, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
[2] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
[3] Scripps Res Inst, Dept Immunol & Microbial Sci, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA
[4] Duke Univ, Duke Human Vaccine Inst, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; PROXIMAL EXTERNAL REGION; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN GP41; T-CELLS; EPITOPE; MEMBRANE; BINDING; 4E10; SPECIFICITIES;
D O I
10.1038/nature11544
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Characterization of human monoclonal antibodies is providing considerable insight into mechanisms of broad HIV-1 neutralization. Here we report an HIV-1 gp41 membrane-proximal external region (MPER)-specific antibody, named 10E8, which neutralizes similar to 98% of tested viruses. An analysis of sera from 78 healthy HIV-1-infected donors demonstrated that 27% contained MPER-specific antibodies and 8% contained 10E8-like specificities. In contrast to other neutralizing MPER antibodies, 10E8 did not bind phospholipids, was not autoreactive, and bound cell-surface envelope. The structure of 10E8 in complex with the complete MPER revealed a site of vulnerability comprising a narrow stretch of highly conserved gp41-hydrophobic residues and a critical arginine or lysine just before the transmembrane region. Analysis of resistant HIV-1 variants confirmed the importance of these residues for neutralization. The highly conserved MPER is a target of potent, non-self-reactive neutralizing antibodies, suggesting that HIV-1 vaccines should aim to induce antibodies to this region of HIV-1 envelope glycoprotein.
引用
收藏
页码:406 / +
页数:9
相关论文
共 50 条
  • [21] Neutralization of HIV-1 by antibody
    Sattentau, QJ
    CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (04) : 540 - 545
  • [22] A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals
    Walker, L. M.
    Simek, M.
    Phogat, S.
    Poignard, P.
    Burton, D. R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (10) : A43 - A43
  • [23] A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals
    Walker, Laura M.
    Simek, Melissa D.
    Priddy, Frances
    Gach, Johannes S.
    Wagner, Denise
    Zwick, Michael B.
    Phogat, Sanjay K.
    Poignard, Pascal
    Burton, Dennis R.
    PLOS PATHOGENS, 2010, 6 (08) : 11 - 12
  • [24] Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency
    Andrianov, Alexander M.
    Kashyn, Ivan A.
    Tuzikov, Alexander V.
    JOURNAL OF BIOINFORMATICS AND COMPUTATIONAL BIOLOGY, 2018, 16 (02)
  • [25] Passive administration of the anti-HIV gp41-specific human monoclonal antibody 2F5 delays, but does not prevent, a primary HIV-1 isolate from establishing an infection in chimpanzees
    Conley, AJ
    Kessler, JA
    Boots, LJ
    McKenna, PM
    Schleif, WA
    Emini, EA
    Katinger, H
    Cobb, EK
    Lunceford, SM
    Rouse, SR
    Murthy, KK
    VACCINES 96 - MOLECULAR APPROACHES TO THE CONTROL OF INFECTIOUS DISEASES, 1996, : 299 - 303
  • [26] P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
    E Gray
    P Moore
    N Ranchobe
    M Abrahams
    M Madiga
    K Mlisana
    S Abdool-Karim
    C Williamson
    L Morris
    Retrovirology, 6
  • [27] Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
    Pinto, Dora
    Fenwick, Craig
    Caillat, Christophe
    Silacci, Chiara
    Guseva, Serafima
    Dehez, Francois
    Chipot, Christophe
    Barbieri, Sonia
    Minola, Andrea
    Jarrossay, David
    Tomaras, Georgia D.
    Shen, Xiaoying
    Riva, Agostino
    Tarkowski, Maciej
    Schwartz, Olivier
    Bruel, Timothee
    Dufloo, Jeremy
    Seaman, Michael S.
    Montefiori, David C.
    Lanzavecchia, Antonio
    Corti, Davide
    Pantaleo, Giuseppe
    Weissenhorn, Winfried
    CELL HOST & MICROBE, 2019, 26 (05) : 623 - +
  • [28] Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41
    Montgomery, Donna L.
    Wang, Ying-Jie
    Hrin, Renee
    Luftig, Micah
    Su, Bin
    Miller, Michael D.
    Wang, Fubao
    Haytko, Peter
    Huang, Lingyi
    Vitelli, Salvatore
    Condra, Jon
    Liu, Xiaomei
    Hampton, Richard
    Carfi, Andrea
    Pessi, Antonello
    Bianchi, Elisabetta
    Joyce, Joseph
    Lloyd, Chris
    Geleziunas, Romas
    Bramhill, David
    King, Vicki M.
    Finnefrock, Adam C.
    Strohl, William
    An, Zhiqiang
    MABS, 2009, 1 (05) : 462 - 474
  • [29] Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41
    Blish, Catherine A.
    Nguyen, Minh-An
    Overbaugh, Julie
    PLOS MEDICINE, 2008, 5 (01) : 90 - 103
  • [30] Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
    Schommers, Philipp
    Gruell, Henning
    Abernathy, Morgan E.
    Tran, My-Kim
    Dingens, Adam S.
    Gristick, Harry B.
    Barnes, Christopher O.
    Schoofs, Till
    Schlotz, Maike
    Vanshylla, Kanika
    Kreer, Christoph
    Weiland, Daniela
    Holtick, Udo
    Scheid, Christof
    Valter, Markus M.
    van Gils, Marit J.
    Sanders, Rogier W.
    Vehreschild, Joerg J.
    Cornely, Oliver A.
    Lehmann, Clara
    Faetkenheuer, Gerd
    Seaman, Michael S.
    Bloom, Jesse D.
    Bjorkman, Pamela J.
    Klein, Florian
    CELL, 2020, 180 (03) : 471 - +